Richard N van Zyl-Smit
Overview
Explore the profile of Richard N van Zyl-Smit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Zyl-Smit R, Filby S, Soin G, Hoare J, van den Bosch A, Kurten S
EClinicalMedicine
. 2025 Jan;
78():102970.
PMID: 39764547
Background: The WHO has highlighted that: "promotion of e-cigarettes has led to marked increases in e-cigarette use by children and adolescents." The long-term neuropsychiatric and psychological consequences of substance abuse...
2.
Ison M, Papi A, Athan E, Feldman R, Langley J, Lee D, et al.
Clin Infect Dis
. 2024 Jan;
78(6):1732-1744.
PMID: 38253338
Background: The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety...
3.
Katoto P, Bihehe D, Brand A, Mushi R, Kusinza A, Alwood B, et al.
Environ Health
. 2024 Jan;
23(1):6.
PMID: 38233832
Background: In low- and middle-income countries countries, millions of deaths occur annually from household air pollution (HAP), pulmonary tuberculosis (PTB), and HIV-infection. However, it is unknown whether HAP influences PTB...
4.
Stone E, Evison M, van Zyl-Smit R, Andarini S, Shah S, Vandeleur M
Lancet
. 2023 Nov;
404(10452):504-506.
PMID: 37924826
No abstract available.
5.
Katoto P, Bihehe D, Brand A, Mushi R, Kusinza A, Alwood B, et al.
Res Sq
. 2023 Oct;
PMID: 37886487
Background: In developing countries, millions of deaths occur annually from household air pollution (HAP), pulmonary tuberculosis (PTB), and HIV-infection. However, it is unknown whether HAP influences PTB risk among people...
6.
Amaral A, Potts J, Knox-Brown B, Bagkeris E, Harrabi I, Hacene Cherkaski H, et al.
Int J Epidemiol
. 2023 Oct;
52(6):e364-e373.
PMID: 37862437
No abstract available.
7.
van Zyl-Smit R, Kerstjens H, Maspero J, Tanase A, Lawrence D, Mezzi K, et al.
Pulm Ther
. 2023 Aug;
9(3):395-409.
PMID: 37526856
Introduction: GINA guidelines recommend increasing the dose of inhaled corticosteroids (ICS) as a step-up option for patients with inadequately controlled asthma at GINA step 4 [inadequately controlled asthma on medium-dose...
8.
van Zyl-Smit R, Kerstjens H, Maspero J, Kostikas K, Hosoe M, Tanase A, et al.
Respir Med
. 2023 Mar;
211:107172.
PMID: 36906187
Background: A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler® is the first inhaled corticosteroid/long-acting ꞵ-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy approved for the maintenance treatment...
9.
Papi A, Ison M, Langley J, Lee D, Leroux-Roels I, Martinon-Torres F, et al.
N Engl J Med
. 2023 Feb;
388(7):595-608.
PMID: 36791160
Background: Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection, lower respiratory tract disease, clinical complications, and death in older adults. There is currently no licensed vaccine...
10.
van Zyl-Smit R, Chapman K, Kerstjens H, Gessner C, Sagara H, Tanase A, et al.
J Asthma Allergy
. 2023 Jan;
16:123-134.
PMID: 36714049
Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler have been approved for the maintenance treatment of patients with asthma inadequately controlled with...